CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 119 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $191,921 | -79.5% | 6,085 | -81.7% | 0.00% | -80.0% |
| Q3 2022 | $938,000 | +241.1% | 33,207 | +291.3% | 0.01% | +66.7% |
| Q4 2021 | $275,000 | -47.6% | 8,486 | -52.3% | 0.00% | -57.1% |
| Q3 2021 | $525,000 | +17400.0% | 17,809 | +17709.0% | 0.01% | – |
| Q2 2021 | $3,000 | -40.0% | 100 | -75.0% | 0.00% | – |
| Q1 2021 | $5,000 | -97.5% | 400 | -96.7% | 0.00% | -100.0% |
| Q4 2020 | $201,000 | – | 12,125 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |